Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 2Multiple Myeloma 2Melanoma 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Hodgkin Disease 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Vorinostat 2Stem Cell Transplantation 2Rituximab 2Gemcitabine 2Busulfan 2Brentuximab Vedotin 2romidepsin 1pembrolizumab 1molibresib 1entinostat 1copanlisib 1belinostat 1Tacrolimus 1Pyridoxine 1Panobinostat 1Mycophenolic Acid 1Melphalan 1Health Resources 1Granulocyte Colony-Stimulating Factor 1Glutamine 1Filgrastim 1Fibroblast Growth Factor 7 1Dexamethasone 1Cyclophosphamide 1Cryotherapy 1Clofarabine 1Calcium Dobesilate 1CT-P10 1Bortezomib 1BI 6727 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, T-Cell × Panobinostat × Clear all
NCT02961816 2017-04-21

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡